Table 1.
Recommended daily warfarin doses (mg/day) to achieve a therapeutic INR based on CYP2C9 and VKORC1 genotype using the warfarin product insert approved by the US Food and Drug Administration
VKORC1:–1639G>A | CYP2C9*1/*1 | CYP2C9*1/*2 | CYP2C9*1/*3 | CYP2C9*2/*2 | CYP2C9*2/*3 | CYP2C9*3/*3 |
---|---|---|---|---|---|---|
GG | 5–7 | 5–7 | 3–4 | 3–4 | 3–4 | 0.5–2 |
GA | 5–7 | 3–4 | 3–4 | 3–4 | 0.5–2 | 0.5–2 |
AA | 3–4 | 3–4 | 0.5–2 | 0.5–2 | 0.5–2 | 0.5–2 |
Reproduced from updated warfarin (Coumadin) product label.